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A B S T R A C T
Infection of mice with Citrobacter rodentium serves as a model to study human intestinal
infections. C. rodentium infection leads to increased production of inflammatory cytokines,
immune cell infiltration and damage to the gut barrier. We used this model of colitis to
evaluate the therapeutic properties of OM-X®, an extract prepared by fermentation of
vegetables, seaweeds, fruits and mushrooms. Administration of OM-X® to C. rodentium-
infected mice reduced damage to the intestinal epithelium, lowered inflammation scores,
increased IL-10 expression and maintained FoxP3 gene expression. OM-X® also partially pre-
vented bacterial translocation, increased expression of tight junction genes and increased
proliferation of epithelial cells. PCR analysis of stool samples showed that OM-X® signifi-
cantly reduced the populations of bacteria harboring buk gene (mostly Clostridium species).
It is suggested that alterations of microbiota composition, following OM-X® consumption,
contribute to protection against infection and epithelial damage, and lead to an increased
expression of anti-inflammatory cytokines.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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The mouse pathogen Citrobacter rodentium belongs to the family
of attaching and effacing (A/E) bacterial pathogens (Schauer
& Falkow, 1993), which also includes the important human
pathogens enterohemorrhagic Escherichia coli (EHEC) and en-
teropathogenic E. coli (EPEC) (Mundy, MacDonald, Dougan,
Frankel, & Wiles, 2005). EPEC causes watery diarrhea, fever and
nausea and is an important cause of infant diarrheal disease
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in developing countries (Kapar, Nataro, & Mobley, 2004). In con-
trast, EHEC infection is associated with sporadic outbreaks
across industrialized countries, due to the consumption of con-
taminated food or water supplies (Welinder-Olsson & Kaifser,
2005).
C. rodentium infection in mice can be used as a model to de-
termine the role of early host factors, such as innate immune
functions and effector cells, in intestinal inflammation. Oral
C. rodentium infection of normal adult mice causes transient
colonization of the caecum and colon,which peaks after 1 week,
and resolves after 3–4 weeks (Maaser et al., 2004; Simmons et al.,
2003; Wiles et al., 2004). In pathologic terms, mild colitis with
epithelial hyperplasia, tight junction disruption, loss of goblet
cells and mucosal infiltration of neutrophils and T cells were
reported (Guttman, Samji, Li, Vogi, & Finlya, 2006; Rodrigues,
Sousa, Johnson-Henry, Sherman, & Gareau, 2012; Wiles et al.,
2004).
The possible curative effect of probiotics on mice infected
by C. rodentium has been investigated (Chen, Louie, Shi, &
Walker, 2005; Rodrigues et al., 2012). Probiotics are live micro-
organisms that are ingested to promote beneficial effects on
health by altering indigenous microbiota and modulat-
ing host immune response (Ashraf, Vasiljevic, Day, Smith, &
Donkor, 2014; Sanders et al., 2013). Preadministration and
coadministration of probiotic mixture containing Lactobacil-
lus helveticus and Lactobacillus rhamnosus improved C. rodentium-
induced barrier dysfunction, epithelial hyperplasia, and binding
of the pathogen to host colonocytes (Chen et al., 2005). Fur-
thermore, some effects of prebiotics were reported. Prebiotics
are defined as “non-digestible food ingredients that benefi-
cially affect the host by selectively stimulating the growth and/
or activity of one or a limited number of bacteria in the colon,
thus improving host health”. Some prebiotic substances reduce
intestinal inflammation and contribute to the recovery of
damaged colonic mucosa (Al-Sheraji et al., 2013; Lara-Villoslada
et al., 2006; Peshev & Van den Ende, 2014; Yousef, Pichyangkura,
Soodvilai, Chatsudthipong, & Muanprasat, 2012).
This study was aimed to evaluate the therapeutic proper-
ties of oral administration of vegetable fermented extract
(OM-X®) in a model of colitis induced by C. rodentium in mice.
OM-X® is a mixture of vegetables, fruits, seaweeds and mush-
rooms naturally fermented using 12 strains of lactic acid bac-
teria and bifidobacteria. Final fermentation product is a paste
rich in live lactic acid bacteria, metabolites and nutrients. OM-
X® has potential probiotic and prebiotic activities; its safety
for human consumption has been demonstrated (Spierings,
Walshe, & Pescatore, 2013), and its beneficial effects on bone
health (Kawakami et al., 2003), oral ulcerations (Hashim,
Rahman, & Philip, 1999), and acute non-bloody diarrhea (local
study) have been shown in human clinical studies. We hy-
pothesized that pre-treatment with OM-X® before C. rodentium
inoculation would exert a protective effect against infection
and improve mucosal immune response, contributing to en-
hanced protection and attenuation of Citrobacter-mediated in-
testinal injury. Furthermore, in order to evaluate the prebiotic
effect of OM-X®, we looked at changes of gut flora composi-
tion in animals treated with OM-X®, vs. untreated animals.We
used an approach based on the PCR quantification of func-
tional genes, but gene coding for butyryl-CoA:acetate CoA-
transferase which is involved in the synthesis of butyrate and
mostly found in species like Faecalibacterium, Roseburia, Eubac-
terium, and buk gene coding for butyrate kinase, mostly present
in Clostridium species (Vital et al., 2013).
2. Materials and methods
2.1. Test product
OM-X® sample was provided by BIOBANK Co., Ltd. (Okayama,
Japan). OM-X® is a naturally fermented mixture of veg-
etables, fruits, seaweeds and mushrooms using 12 strains of
lactic acid bacteria and bifidobacteria. After 5 years of fermen-
tation, the fermented mixture contains probiotics, prebiotics
such as oligosaccharides and dietary fiber, trace amounts of
vitamins, minerals, short-chain fatty acids, and amino acids
(see Supplementary Table S1 in the online version at doi:10.1016/
j.jff.2014.06.003).
2.2. Mice, treatment protocols
Female Balb/c mice (Charles River) aged 9 weeks were main-
tained in accredited animal facility at the Institut Pasteur of
Lille according to governmental guidelines. Mice were in-
fected by oral gavage with 0.1 ml of an overnight culture in Luria
broth containing approximately 5 × 108 CFU of wild-type
C. rodentium (formerly Citrobacter freundii biotype 4280 strain
DBS100). OM-X® was resuspended in 0.5% carboxymethylcel-
lulose (CMC) just before oral gavage and administered to mice
at 500 mg/kg/day. Mice were divided into four groups: 1) Control
mice treated with vehicle, 2) Control mice treated with
OM-X®, 3) C. rodentium-infected mice treated with vehicle, 4)
C. rodentium-infected mice treated with OM-X®. OM-X® or
vehicle were administered for 3 weeks before infection of
mice by C. rodentium.Treatment was continued for 10 days, then
animals were sacrificed by cervical dislocation.
2.3. Mortality rate, body weight evolution
Mortality rate and body weight evolution were evaluated
for all four groups, twice a week before infection, daily after
infection.
2.4. Bacterial counting (detection of C. rodentium in
stool samples)
Stools were collected from controls and infected mice at day
2 post-infection, placed in 1.5 ml of PBS, and homogenized.
Homogenates were serially diluted in PBS, plated onto Luria
broth agar plates, incubated overnight at 37 °C, and bacterial
colonies were counted on the following day.
2.5. Intestinal permeability
Mice received by gavage 20 ml/kg body weight of phosphate-
buffered saline (pH 7.4) containing 22 mg/ml fluore-
scein isothiocyanate-conjugated dextran (FITC-dextran,
molecular mass 4.4 kDa; Sigma, St. Louis, MO, USA). A blood
sample (~150 μl) was obtained in a capillary tube 2 h after
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administration of the markers by retro-orbital puncture. Blood
was centrifuged (1200 g at 4 °C) for 20 min. The concentra-
tion of fluorescein was determined by spectrophotofluorometry
(CytoFluo 2300, Millipore, Bedford, MA, USA) with an excita-
tion wavelength of 485 nm and an emission wavelength of
530 nm using serially diluted samples of the marker as
standard.
2.6. Sacrifice, collection of samples
Uninfected mice or mice at day 10 post-infection were anes-
thetized with Halothane and killed by cervical dislocation, and
colons were resected for further analysis; the colons were
divided in half to separate the proximal and distal portions.
Tissues were immediately placed in 4% paraformaldehyde for
histological analysis, or stored at −86 °C for subsequent RNA
extraction. Serum from each animal was collected at the time
of sacrifice. Blood samples were collected by cardiac punc-
ture, placed in a 1.1 ml Z-Gel micro tube (Sarstedt, Nümbrecht,
Germany). Tubes were inverted five times and samples were
then allowed to clot for 1 hour at room temperature.Tubes were
centrifuged at 2300 g over 10 min at 20 °C. Serum (superna-
tant) was collected into a fresh pre-chilled tube and stored at
−80 °C. Stool samples from each animal were collected on day
−21 (before first gavage) and on day 10, before sacrifice.
2.7. Histological assessment of inflammation
Paraffin-embedded colonic tissue sections (5 mm) stained with
hematoxylin and eosin were examined by two blinded observ-
ers. The severity of inflammatory lesions was quantified ac-
cording to Ameho’s criteria (Ameho et al., 1997): tissue sections
were assessed for submucosal edema; epithelial hyperplasia
(score based on percentage above the height of the control);
epithelial integrity (score based on number of epithelial cells
shedding per lesion, epithelial ulceration, epithelial ulcer-
ation with severe crypt destruction); neutrophil and mono-
nuclear cell infiltration. Results were expressed as amean ± SEM
score.
2.8. Bacterial translocation
Upon dissection mesenteric lymph nodes (MLN) and spleen
were collected and conserved for up to 2 hours in Ringer/
Tween 80 medium under anaerobic conditions. After homog-
enization, samples were incubated in Brain Heart Broth. Ten
and hundred time dilutions were performed in Ringer cystein
medium. These dilutions were spread out on CS ANA plates
(Columbia agar enriched with 5% defibrinated horse blood) and
Mc Conkey plates, and incubated at 37 °C under aerobe or an-
aerobe atmosphere. Colonies were counted and identified 2 and
7 days after spreading.
2.9. MPO quantification
Myeloperoxydase (MPO) is an enzyme contained in poly-
morphonuclear neutrophil primary granules and is used as a
marker of neutrophil infiltration. Proteins were extracted from
the whole colon using an extraction buffer (200 mMNaCl, 5 mM
ethylenediaminetetraacetic acid (EDTA), 10 mMTris, 10% glyc-
erin, 1 mM PMSF, 1 µg/ml leupeptin and 28 µg/ml aprotinin,
pH 7.4). Proteins were quantified, MPO level was measured by
ELISA (Clinisciences, Nanterre, France) according to manufac-
turer’s instructions.
2.10. Evaluation of gene expression in the colonic wall by
real-time qPCR
Total RNA was isolated from colonic tissue using RNeasy kit
(Macherey Nagel, Hoerdt, France) according to manufactur-
er’s instructions. RNA concentration was determined by
spectrophotometry. After treatment at 37 °C for 30 min with
20–50 units of RNase-free DNase I (Roche Diagnostics Corpo-
ration, Indianapolis, IN, USA), oligo-dT primers (Roche Diag-
nostics Corporation) and “High capacity cDNA reverse
transcription kit” (Applied Biosystems, Gent, Belgium) were used
to synthesize single-stranded cDNA. PCR was performed using
SYBR green Master Mix (Applera, Courtaboeuf, France) with
murine specific oligonucleotides (see Supplementary Table S2
in the online version at doi:10.1016/j.jff.2014.06.003) in a
GeneAmp Abiprism 7000 (Applera). In each assay, calibrated
and no-template controls were included. Each sample was run
in triplicate. SYBR green dye intensity was analyzed using
the Abiprism 7000 SDS software (Applera). All results were
normalized to the housekeeping gene GAPDH.
2.11. Proliferation and apoptosis of colonic epithelial cells
Colonic tissue was immediately placed in 4% paraformalde-
hyde solution for histological studies. Evaluation of epithelial
cell proliferation was performed by immunohistochemistry
using a rabbit polyclonal anti-PCNA antibody (Santa Cruz
Corporation, Santa Cruz, CA, USA).Tissues were incubated with
the primary anti-PCNA antibody at a concentration of 1/100e
diluted in PBS + 0.5% Tween 20 and 3% goat serum overnight
at 4 °C. A secondary antibody (anti-goat rabbit Alexa-fluor 488,
1/100e, 1 h) was used. Hoechst staining was used to stain the
cell’s nucleus. Quantification (green staining-PCNA normal-
ized to blue staining-Hoechst) was performed using ImageJ soft-
ware (Abramoff, Magalhaes, & Ram, 2004).
2.12. Quantification of buk and but gene in the
stool samples
Dried stool samples were weighted and total DNA extracted
using QIAamp DNA stool kit (Qiagen). DNA was eluted in 200 μl
elution buffer. Purity was checked by measuring 260/280 and
260/230 OD ratios. Typically 5–15 μg total DNA were obtained
from each sample; extracted genomic DNAwas stored at −20 °C.
Primers sequences were as described in Supplementary Table S3
in the online version at doi:10.1016/j.jff.2014.06.003. but-
expressing bacteria include several species. Because of sig-
nificant sequence variations in but gene itself it was not possible
to design a single set of primers able to cover all these species.
Two different primer pairs were used, one corresponding to but
sequences found in bacteria related to Faecalibacterium, and one
corresponding to the sequences of Roseburia-related species.
PCR mix was ABsolute Blue QPCR SYBR Green (ABgene, Pitts-
burgh, PA, USA). Optimal hybridization temperature and primer
concentrations were determined for this reagent and are re-
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ported in the Supplementary Table S3 in the online version at
doi:10.1016/j.jff.2014.06.003.
Quantative PCR was performed with a Mastercycler Realplex
thermocycler (Eppendorf, Hamburg, Germany). Samples (100 ng
DNA) were amplified in a total reaction volume of 25 µl con-
taining 12.5 µl ABsolute Blue qPCR SYBR green (2×) and 2.5 µl
of each primer. Thermocycling was done as follows: 15 min at
95 °C then 40 cycles 20 s at 95 °C, 20 s at individual annealing
temperature and 30 s at 72 °C. Bacterial DNAwas extracted from
reference strains using Nucleospin DNA extraction kit,Macherey
Nagel; serial 10-fold dilutions were used to build a standard
curve. The following bacterial strains were used as refer-
ences; buk: Clostridium perfringens LAB (from University of Lille),
but: Faecalibacterium prausnitzii (DSMZ 17677) and Roseburia
intestinalis (DSMZ 14610).
2.13. Statistical analysis
All comparisons were performed using the permutation test
for two independent samples. Statistics have been calculated
using the StatXact software (Cytel Inc, Cambridge, MA, USA).
Differences were considered statistically significant when
p value was <0.05.
3. Results
3.1. OM-X® is safe and well tolerated
The weight of the animals was monitored twice a week before
Citrobacter infection, and daily after infection. Presence of
C. rodentium in the stool of infected animals was confirmed
by culturing stool samples collected on day 2 post-infection;
no C. rodentium was detected in non-infected controls. Admin-
istration of OM-X® did not affect the growth of the animals
(Fig. 1). Histological analysis did not reveal any inflammation
or intestinal lesions in mice which had received OM-X®. As
expected, oral infection by C. rodentium induced a significant
colitis at the histological level with a mean score of 2.5 ± 0.21.
Inflammatory lesions tended to be less severe in mice treated
with OM-X®; however, this protective effect was not signifi-
cant (p = 0.07) (Fig. 2).
MPO activity in the intestine can be used to quantitate in-
flammation. In this study, mice infected with C. rodentium had
Fig. 1 – Effect of treatment on body weight evolution. Number of animals per group: control + vehicle n = 10; control + OM-
X® n = 10; Citrobacter + vehicle n = 15; Citrobacter + OM-X® n = 15.
Fig. 2 – Effect of treatment on histological inflammatory
scores. Unit is Ameho’s score, as defined in Materials and
methods section.
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significantly higher MPO levels compared with healthy control
mice, but this increase was not prevented by OM-X® admin-
istration (data not shown).
3.2. OM-X® inhibits bacterial translocation
Colonic inflammation leads to a modification of intestinal
barrier integrity. Increase of intestinal permeability allows bac-
teria to cross the intestinal barrier from the lumen to mesen-
teric lymph nodes (MLN) and to the spleen through systemic
blood circulation. Evaluation of bacterial translocation was per-
formed in MLN and spleen of each infected mice after homog-
enization of the tissues and culture on selective media: CS ANA,
a non-selective medium, and Mc Conkey which is more spe-
cific for enterobacteria like C. rodentium. Translocation levels
in control mice were below the limit of detection, therefore only
results for C. rodentium-infected mice are provided. A high level
of translocation was observed in the spleen of infected mice
receiving the vehicle, with 64% of the animals showing evi-
dence of translocation. In mice treated with OM-X®, the trans-
location of enterobacteria following Citrobacter infection was
reduced (28.5% vs. 64.3%). In MLN, bacterial translocation was
observed in 42% of the infected mice receiving only the vehicle,
compared with only 21% of themice treated with OM-X®.Taken
together these results indicate that OM-X® exerts a protec-
tive effect against bacterial translocation from the intestinal
lumen to the MLN and the systemic blood circulation (Table 1).
3.3. OM-X® administration alters cytokine responses in
the intestinal mucosa
To investigate the influence of OM-X® treatment on pathogen-
induced cytokine response in the intestinal mucosa, we ex-
amined the expression of cytokine genes in colonic tissue
(Fig. 3). In control mice without colitis, there was no induc-
tion of pro-inflammatory cytokines following OM-X® treat-
ment; however, a significant induction of IFNγ was observed.
C. rodentium caused a significant induction ofTNF-α, which was
not prevented by OM-X®. A significant effect of OM-X® was
seen in infected mice, with a substantial induction of anti-
inflammatory IL-10. Consistent with this induction of IL-10, OM-
X® also had a significant effect on FoxP3 expression, which was
maintained at control levels in OM-X®-treated animals,whereas
animals infected with Citrobacter, but not treated by OM-X®,
showed a significant drop of FoxP3 expression. FoxP3 is spe-
cifically expressed by regulatory T cells (Treg cells), which are
anti-inflammatory regulatory cells present in the mucosa, and
strong producers of IL-10. Our results suggest a role for OM-
X® in immune regulation during enteric bacterial infection.
3.4. OM-X® administration alters expression of tight
junction related genes
Tight junction proteins such as claudins and zonula occludens
bind epithelial cells together and are crucial to maintain the
integrity of the membrane. Dysregulation of their expression
is an indication of membrane damage and increased perme-
ability. Inflammation has been shown to decrease the expres-
sion of tight junction proteins. In control mice without colitis,
OM-X® administration significantly induced the expression of
genes coding for tight junctionproteinsZO-1,ZO-2,and claudin-2
(Fig. 4). Induction was also perceptible in infected animals but
less significant. For claudin-4 the effect was not significant in
control animals, but OM-X® could significant suppress the de-
crease of clandin-4 in infectedmice (p = 0.04).Our results suggest
that OM-X® leads to the reinforcement of the intestinal barrier
by increasing the expression of tight junction proteins.
3.5. Effect of OM-X® on intestinal epithelial
cell proliferation
Cellular proliferation can be evaluated by PCNA (proliferation
cell nuclear antigen) staining. Quantification using ImageJ soft-
ware showed higher staining in OM-X®-treated mice than in
controls. In C. rodentium infected mice, there was virtually no
PCNA staining; however, proliferation again increased follow-
ing treatment with OM-X® (Fig. 5).
3.6. Investigation of butyrate-producing
bacterial communities
We investigated the effect of OM-X® on gut microbiota com-
position (Fig.6). It has indeedbeen shown that colonicmicrobiota
can influence the susceptibility to infectious colitis (Ghosh et al.,
2011). We made the hypothesis that OM-X® could favor the
growth of specific commensal species like Faecalibacterium,
Roseburia, Eubacterium, Acidaminococcus, which are heavy pro-
ducers of butyrate. Butyric acid is a short-chain fatty acid (SCFA)
acting as an essential source of energy for colonocytes, stimu-
lating their proliferation,and exerting anti-inflammatory effects
(Pryde, Duncan, Hold, Stewart, & Flint, 2002).
Instead of focusing on specific bacterial species, we used
an alternative approach based on the quantification of
functional genes as described previously (Vital et al., 2013).The
Table 1 – Bacterial translocation in control, infected mice vs. OM-X®-treated, infected mice.
CS ANA (ns) MLN Infected mice Infected mice + OM-X
+ 6 3
− 8 11
% positive mice 42.8% 21%
Mc Conkey (eb) MLN Infected mice Infected mice + OM-X
+ 3 2
− 11 12
% positive mice 21% 14%
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principle of this approach is to quantify key genes involved in
butyrate synthesis pathways.The enzyme butyryl-CoA:acetate
CoA-transferase (but) is involved in the synthesis of butyrate
from butyryl-CoA; it is found mostly in species like
Faecalibacterium, Roseburia, Eubacterium (Duncan, Barcenilla,
Stewart, Pryde, & Flint, 2002). Another possible pathway of bu-
tyrate synthesis involves butyrate kinase (buk), whose gene is
mostly present in Clostridium species (Clostridium acetobutyricum,
C. perfringens) (Hartmanis, 1987; Louis et al., 2004). The but
pathway appears to be the predominant pathway of butyrate
synthesis in healthy humans. It yields more butyrate than the
buk pathway; it requires acetate as a substrate and therefore
may prevent the accumulation of acetate and lactate in the
gut (Louis & Flint, 2009).
The average count of buk bacteria in stool samples from
control mice was 450,000 cfu/g stool. However, in controls
treated with OM-X®, buk count values significantly dropped
to an average of 220,000 cfu/g stool (p = 0.044). C. rodentium-
infected mice showed a high variability in their buk bacteria
counts. OM-X® was able to decrease the average buk bacteria
count from 346,000 cfu/g (infected mice, OM-X®-treated) to
250,000 cfu/g (infected mice, not treated); however, because of
the high variability between animals this decrease did not reach
statistical significance.
Fig. 3 – Expression of cytokine genes in colon tissue (real-time qPCR). Relative units: ratio target gene expression over
GAPDH expression.
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but bacteria were clearly dominant compared with buk bac-
teria, with typical count numbers between 5 and 15 billion cfu/g
stool for the Faecalibacterium-related species, and 2–4 billion for
Roseburia-related species.There was a moderate increase of but
bacteria related to Faecalibacterium in control mice treated with
OM-X®, compared with controls that received only vehicle.
The counts of Roseburia-related species were similar in both
groups. Using both primer sets, a highly significant drop of but
Fig. 4 – Expression of tight-junction genes in colon tissue (real-time qPCR). Relative units: ratio target gene expression over
GAPDH expression.
Fig. 5 – Evaluation of cellular proliferation by PCNA staining. Blue: Hoechst staining; green: PCNA staining, indicating
proliferation. Quantification is provided as ratio of green staining over blue staining, using ImageJ software (Abramoff
et al., 2004).
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bacteria counts was observed following C. rodentium infec-
tion (from 10.3 × 109 to 2.28 × 109 cfu/g stool, p = 0.028 for
Faecalibacterium-related species; from 2.7 × 109 to 0.25 × 109 cfu/g
stool, p = 0.0007 for Roseburia-related species). Treatment of
infected animals with OM-X® tended to prevent this drop.
The mean count was back to 9.25 × 109 cfu/g stool for
Faecalibacterium-related species, and to 0.63 × 109 cfu/g stool
for Roseburia-related species. However because of the
variability between animals these trends did not reach
significance.
4. Discussion
Although histological analysis of the intestinal wall did not
reveal any significant improvement of C. rodentium-induced
colitis in mice treated with OM-X® (a trend could be
observed, but not statistically significant, p = 0.07), a signifi-
cant effect was observed at the molecular level since in-
fected mice treated with OM-X® showed an increased
expression of the anti-inflammatory cytokine IL-10. Major
producers of IL-10 are Treg cells, which are crucial effectors
of tolerogenic and anti-inflammatory pathways in the gut mem-
brane (Geiger & Tauro, 2012; Murai et al., 2009). Citrobacter in-
fection reduced the colonic expression of FoxP3, a specific
marker of Treg cells. The levels of FoxP3 expression were
however restored in infected mice which had received OM-
X®. Increased expression of FoxP3 indicates full maturation of
Treg cells and activation of their suppressive capacity, and/or
could also result from an increased number of Treg cells in the
mucosa (recruitment).
In Citrobacter infection, like in any other type of infection,
the immune system must keep a balance between activation
that clears up the pathogen, and excessive inflammation that
would lead to tissue damage. Induction ofTreg had already been
observed in the context of Citrobacter infection (Symonds et al.,
2009) and was interpreted as a mechanism to prevent exces-
sive colitis and epithelium destruction. Our results suggest that
OM-X® treatment will reinforce the suppressive arm of the
immune response, leading to a reduction of inflammation
and better protection of membrane integrity. Interestingly
induction of IFNγ, which was observed in mice treated with
OM-X®, could have the same biological relevance. Although
IFNγ is considered as pro-inflammatory, it has indeed been
shown to exert a crucial homeostatic function that limits
inflammation-related tissue damage, through multiple mecha-
nisms including inhibition of matrix metalloproteinases and
complement components (Hu & Ivashkiv, 2009). This protec-
tive action of IFNγ has been described in particular in the
context of mouse colitis (Thelemann et al., 2014).
Maintenance of intestinal barrier function is crucial to
prevent microorganisms and luminal antigens from entering
the body. Proper barrier function depends on epithelial cells
renewal, as well as on the capacity of cells to tightly adhere
to each other in order to form a continuous lining. The secre-
tion of mucus by specialized cells in the mucosa also contrib-
utes to membrane impermeability. We found that OM-X®
administration resulted in a significant decrease of bacterial
translocation to spleen and MLN, which is an indication of
improved intestinal barrier function. Furthermore, OM-X®
was able to increase significantly the expression of tight junc-
tion proteins (ZO-1, ZO-2, claudin-2, and claudin-4), which
are playing an important role in the reinforcement of the gut
membrane (Fanning & Anderson, 2009; Liu et al., 2013; Tsukita
et al., 2009).
An intriguing result of our study was the increased prolif-
eration of colonic epithelial cells observed in infected animals
treated with OM-X®. Although hyperplasia is a hallmark of
Citrobacter infections, in our experiment very little prolifera-
tion was observed in infected animals. Most probably the Balb/c
mice used in our study, which are known to display little
Fig. 6 – buk and but bacterial gene quantification in mouse
stool samples. Expressed in cfu/g stool.
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sensitivity to Citrobacter infection (Mundy et al., 2005), had
already cleared most of the pathogens; the increased prolif-
eration associated with OM-X®, which was associated with de-
creased translocation and improvement of barrier function
markers, should therefore be interpreted as part of a gut mucosa
repair process, contributing to wound healing and mainte-
nance of barrier function. Failure to properly repair lesions in
the gut mucosa indeed leads to disruption of the barrier and
is a key feature of colitis (Iizuka & Konno, 2011).
Bacterial translocation is a natural process but excessive
translocation can lead to infections and various inflammation-
related disorders (Balzan, de Almeida-Quadros, de Cleva,
Zilberstein, & Cecconello, 2007; Ilan, 2012; Klatt, Funderburg,
& Brenchley, 2013). The ability of OM-X® to restore mem-
brane integrity and reduce bacterial translocation is there-
fore highly beneficial, and opens possibilities of applications
for the prevention of several health disorders. It is known that
butyrate produced by commensal bacteria belonging to Clos-
tridium IV and XIVa clusters can exert beneficial effects in-
cluding increased IL-10 expression, recruitment of Treg cells
in the gut membrane and proliferation of epithelial cells (Arpaia
et al., 2013; Atarashi et al., 2011, 2013; Furusawa et al., 2013).
The abundance of each of these groups is estimated by fluo-
rescent in situ hybridization at around 2–15% of the total
microbiota (Louis & Flint, 2009). However, both clostridial clus-
ters comprise several bacterial species, some butyrate produc-
ers and some non butyrate producers. In order to quantify
the populations of butyrate-producing bacteria we used an
approach based on analysis of functional genes related to bu-
tyrate synthesis pathways, instead of focusing on bacterial
16S rRNA sequences (Vital et al., 2013). Real-time PCR analy-
sis was performed to quantify the amount of but sequences
(present in Faecalibacterium, Roseburia, Eubacterium) and buk se-
quences (present in Clostridium s.s. species). OM-X® was able
to reduce buk populations in control mice, and this effect was
significant (p = 0.044). A similar trend (however not signifi-
cant, because of sample variability) was observed in C. rodentium-
infected mice.
Bacteria containing but sequences were detected at much
higher levels than bacteria containing buk sequences, and there-
fore represent the predominant butyrate-synthesizing organ-
isms in healthy mice. C. rodentium infection induced a dramatic
drop of butyrate-producing organisms, possibly contributing
to the inflammation and increased permeability seen in
infected mice. In both controls and Citrobacter-infected mice,
administration of OM-X® tended to increase the counts of but
bacteria; however, this effect was not significant.
Taken together these results are encouraging, demonstrat-
ing the capacity of OM-X® to improve the composition of the
gut microbial composition in mice, by significantly decreas-
ing the amount of buk bacteria and slightly favoring the growth
of but populations. These results therefore suggest a prebi-
otic effect of OM-X®. During manufacturing of OM-X®, which
is a non heated process, the Maillard reaction results in the
accumulation of melanoidin (data not shown). Melanoidin is
an end-product typically found in fermented food, and its ca-
pacity to alter gut microbiota composition has already been
reported (Fogliano & Morales, 2011). Modification of the buk/
but bacterial balance in animals consuming OM-X®may there-
fore be the result of melanoidin ingestion.
A particularly interesting finding is the capacity of
OM-X® to reduce the counts of bacteria carrying the buk gene.
Clostridium difficile and C. perfringens are two carriers of buk gene
(Aboulnaga et al., 2013), known to produce toxins which can
alter intestinal permeability, predominantly by opening the
mucosa tight junction (Goldstein et al., 2009; Hansen et al., 2013).
These results confirm previous (Y. Miyake, 2006) data showing
the in vitro anti-microbial effect of OM-X® against C. difficile.
The capacity to inhibit these pathogenic organisms is an
interesting property, which could find applications such as
the prevention or treatment of C. difficile infections following
antibiotic treatment.
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